<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565315/" ref="ordinalpos=231&amp;ncbi_uid=4694573&amp;link_uid=PMC3565315" image-link="/pmc/articles/PMC3565315/figure/f1-ijms-14-01179/" class="imagepopup">Figure 1.  From: Hedgehog <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span> in Ovarian Cancer. </a></div><br /><div class="p4l_captionBody">Overview of the Hedgehog signaling pathway: a simplified model for Hh signaling in mammalian cells. SMO is the key transducer of the Hh pathway. (<b>a</b>) In the absence of the Hh ligands, the putative Hh receptor PTC is localized in the cilium and inhibits SMO signaling. Gli molecules are processed with the help of Su(Fu)/KIF7 molecules into repressor forms, which deactivate the Hh signaling pathway. (<b>b</b>) In the presence of Hh, PTC is displaced out of the cilium and unable to inhibit SMO. Hh reception facilitates conformational changes in SMO, promoting Gli activation (GliA) and stimulation of Hh target gene expression. Su(Fu) and KIF7 can inhibit this process.</div></div>